3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Prostatic Neoplasms
7
Lymphoma
5
Burkitt Lymphoma
5
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Leukemia
2
Endometrial Neoplasms
2
Down Syndrome
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Lymphoma, T-Cell, Peripheral
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Heart Failure
1
Enteropathy-Associated T-Cell Lymphoma
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Prednisolone
×
1 year
×
Clear all
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled